Physician profile
Anna Symolon
NPI 1174501589
$1,392.28
in general payments reported to CMS, 2019-2025
13 companies · $456 in 2025
The $456 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $12.05 · 2021: $43.21 · 2022: $220 · 2023: $255 · 2024: $294 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $298.56 | 2022-2024 | Tyrvaya |
| Alcon Vision LLC | $271.71 | 2020-2025 | Rocklatan |
| Bausch & Lomb Americas INC. | $232.00 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $143.07 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $95.28 | 2021-2025 | Cequa |
| Allergan, INC. | $84.46 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $78.01 | 2022-2023 | Acuvue |
| Novartis Pharmaceuticals Corporation | $52.39 | 2023 | |
| Visioneering Technologies, INC. | $50.30 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $43.89 | 2024 | Lipiflow System Activator II (Disposable |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.06 | 2019 | |
| Dompe US, INC. | $15.56 | 2023 | Oxervate |
| Abb Con-Cise Optical Group LLC | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Symolon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.